Drug Development, Tax Breaks, Future Reimbursement Expected After Medical Marijuana …
Federal policy changes around cannabis drug development tax incentives could reshape medical cannabis access and research funding. Understanding these regulatory shifts helps clinicians prepare for evolving therapeutic landscapes while maintaining focus…
GLP-1 Receptor Agonist Clinical Evidence and R&D Returns
GLP-1 receptor agonist pharmaceutical development has surged due to growing clinical evidence supporting their efficacy. This development reflects significant R&D returns in metabolic medicine. Understanding this trend is crucial for prescribers managing…
Aelis Farma Reports Its 2025 Annual Financial Results and Confirms Its 2026 Outlook
Aelis Farma announced its financial results for 2025, highlighting progress in cannabis use disorder treatment development. The 2026 outlook confirms continued clinical trial advancements. This report focuses on Aelis Farma financial results 2025 and…
